Functional assay helps predict patient response to MM therapies

In a study published in Nature Communications, researchers at Massachusetts Institute of Technology and colleagues found mass accumulation rates (MAR) of treated myeloma cells correlated to patient response to standard-of-care multiple myeloma therapies, suggesting a functional assay to help treat relapsed MM.

The team previously showed that single cells sensitive to small molecule therapies exhibit reduced MAR while resistant cells maintain MARs in acute lymphocytic leukemia (ALL) and glioblastoma models...